On Wednesday, Boral (OTC:BOALY) Capital initiated coverage on Coya Therapeutics (NASDAQ:COYA), assigning a Buy rating to the stock along with a $15.00 price target.
The firm's analysis is based on Coya's innovative approach to treating neurodegenerative disorders by targeting brain inflammation.
According to the firm's coverage, Coya Therapeutics is working on a treatment that modulates the immune system to benefit patients with Amyotrophic Lateral Sclerosis (ALS). The company's strategy involves the precise application of IL-1 and CTLA4 to balance T-regulatory and T-effector cells, which are believed to play a role in the rapid progression of ALS.
The optimism surrounding the company stems from a small Proof-of-concept study that indicated the potential effectiveness of Coya's method. This preliminary success has paved the way for a larger Phase 2 study, which Coya Therapeutics plans to initiate to further validate its approach.
"Coya developed a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain," the analysts at the firm said.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.